Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report
Glioblastoma (GBM) is the most common malignant brain tumor. Less than 1% of patients survive longer than 10 years. A 77-year-old woman was diagnosed with MGMT-methylated GBM in 2009. The patient received cilengitide as part of the CENTRIC clinical trial in conjunction with standard radiation and ch...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis Group
2023-06-01
|
| Colecção: | CNS Oncology |
| Assuntos: | |
| Acesso em linha: | https://www.futuremedicine.com/doi/10.2217/cns-2022-0017 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|